Legal Risks Complicate Drugmakers' TrumpRx Participation
A federal watchdog issued a rare bulletin last week — its first in almost 12 years — assuring drugmakers that they can sell directly to patients through the planned TrumpRx site without facing...To view the full article, register now.
Already a subscriber? Click here to view full article